News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Sarepta Therapeutics, Inc.
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
April 24, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics to Present at Upcoming Investor Conferences
March 04, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
February 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
February 28, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
February 21, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
February 16, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 31, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
January 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
January 16, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue
January 08, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 29, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status
December 22, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 30, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics to Present at the UBS Biopharma Conference
November 02, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments
November 01, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 31, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy
October 30, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics to Announce Third Quarter 2023 Financial Results
October 25, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 29, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year
September 07, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 05, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 31, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments
August 02, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics to Announce Second Quarter 2023 Financial Results
July 26, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 million
July 05, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics to Present at Cowen's 2nd Annual RNA Therapeutics Summit
July 03, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.